Trial record 35 of 58 for:
"Aspergillosis" | "Cytochrome P-450 CYP3A Inhibitors"
CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03731169 |
|
Recruitment Status :
Recruiting
First Posted : November 6, 2018
Last Update Posted : November 6, 2018
|
Sponsor:
University Health Network, Toronto
Information provided by (Responsible Party):
Marisa Battistella, University Health Network, Toronto
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2019 |
| Estimated Study Completion Date : | June 2019 |